Your browser doesn't support javascript.
loading
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat, Aleix; Guarneri, Valentina; Pascual, Tomás; Brasó-Maristany, Fara; Sanfeliu, Esther; Paré, Laia; Schettini, Francesco; Martínez, Débora; Jares, Pedro; Griguolo, Gaia; Dieci, Maria Vittoria; Cortés, Javier; Llombart-Cussac, Antonio; Conte, Benedetta; Marín-Aguilera, Mercedes; Chic, Nuria; Puig-Butillé, Joan Anton; Martínez, Antonio; Galván, Patricia; Tsai, Yi-Hsuan; González-Farré, Blanca; Mira, Aurea; Vivancos, Ana; Villagrasa, Patricia; Parker, Joel S; Conte, Pierfranco; Perou, Charles M.
Afiliación
  • Prat A; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; SOLTI cooperative group, Barcelona, Spain; Department of Medicine, University of Barcelona
  • Guarneri V; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Pascual T; SOLTI cooperative group, Barcelona, Spain.
  • Brasó-Maristany F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Sanfeliu E; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Paré L; Reveal Genomics, Barcelona, Spain.
  • Schettini F; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; SOLTI cooperative group, Barcelona, Spain.
  • Martínez D; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Jares P; Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain; Molecular Biology CORE laboratory, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Griguolo G; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Dieci MV; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Cortés J; Institute of Oncology (IOB)-Quiron, Madrid, Spain; Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Llombart-Cussac A; Department of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain.
  • Conte B; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; SOLTI cooperative group, Barcelona, Spain.
  • Marín-Aguilera M; Reveal Genomics, Barcelona, Spain.
  • Chic N; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clinic of Barcelona, Spain; SOLTI cooperative group, Barcelona, Spain.
  • Puig-Butillé JA; Molecular Biology CORE laboratory, Hospital Clinic de Barcelona, Barcelona, Spain; Biochemistry and Molecular Genetics Service, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Martínez A; Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Galván P; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Tsai YH; Reveal Genomics, Barcelona, Spain.
  • González-Farré B; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain.
  • Mira A; Centro de Diagnóstico Biomédico, Hospital Clinic, Barcelona, Spain.
  • Vivancos A; Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Villagrasa P; Reveal Genomics, Barcelona, Spain.
  • Parker JS; Life Edit Therapeutics, North Carolina, USA.
  • Conte P; Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
  • Perou CM; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, USA.
EBioMedicine ; 75: 103801, 2022 Jan.
Article en En | MEDLINE | ID: mdl-34990895
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: EBioMedicine Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Female / Humans Idioma: En Revista: EBioMedicine Año: 2022 Tipo del documento: Article